Skip to main content
. Author manuscript; available in PMC: 2014 Aug 15.
Published in final edited form as: J Immunol. 2013 Jul 3;191(4):1606–1613. doi: 10.4049/jimmunol.1301116

Figure 3. Inhibition of Notch1 or Notch1/Notch2 protects from EAE independently of changes in Th1 and Th17 differentiation.

Figure 3

(A) Percent disease incidence (score ≥2) of immunized WT, Notch1-deficient (N1KO) and Notch1/2-deficient (N1/2DKO) mice (2 experiments); (B) Number of IFNγ and IL-17A-secreting cells by ELISpot in the DLN from immunized WT and N1KO (n=2–3 mice/group; ≥2 experiments). Frequency of T-bet+CD44+CD4+ N1KO T cells as assessed by intracellular flow cytometry (2 experiments; n=3–4 mice/group); (C) Number of IFNγ and IL-17A-secreting cells by ELISpot in DLN from immunized WT and N1/2DKO (n=2–3 mice/group; ≥2 experiments). Frequency of T-bet+CD44+CD4+ N1/2DKO T cells as assessed by intracellular flow cytometry (2 experiments; n=3–4 mice/group). p<0.05*; p<0.001***.